BR112014016736A2 - composto, composição farmacêutica, método para tratamento, uso de um composto e invenção - Google Patents
composto, composição farmacêutica, método para tratamento, uso de um composto e invençãoInfo
- Publication number
- BR112014016736A2 BR112014016736A2 BR112014016736A BR112014016736A BR112014016736A2 BR 112014016736 A2 BR112014016736 A2 BR 112014016736A2 BR 112014016736 A BR112014016736 A BR 112014016736A BR 112014016736 A BR112014016736 A BR 112014016736A BR 112014016736 A2 BR112014016736 A2 BR 112014016736A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- treatment
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/587—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
- C07D277/593—Z being doubly bound oxygen or doubly bound nitrogen, which nitrogen is part of a possibly substituted oximino radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the nitrogen atom of at least one of the carboxamide groups further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/20—Esters of monothiocarboxylic acids
- C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261591299P | 2012-01-27 | 2012-01-27 | |
US201261678669P | 2012-08-02 | 2012-08-02 | |
PCT/EP2013/051082 WO2013110578A1 (en) | 2012-01-27 | 2013-01-22 | Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014016736A2 true BR112014016736A2 (pt) | 2017-06-13 |
BR112014016736A8 BR112014016736A8 (pt) | 2017-07-04 |
Family
ID=47628132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014016736A BR112014016736A8 (pt) | 2012-01-27 | 2013-01-22 | composto, composição farmacêutica, método para tratamento, uso de um composto e invenção |
Country Status (12)
Country | Link |
---|---|
US (1) | US9586916B2 (pt) |
EP (1) | EP2806899B1 (pt) |
JP (1) | JP6316209B2 (pt) |
KR (1) | KR20150009952A (pt) |
CN (1) | CN104144706B (pt) |
BR (1) | BR112014016736A8 (pt) |
CA (1) | CA2856619A1 (pt) |
ES (1) | ES2605939T3 (pt) |
HK (1) | HK1202426A1 (pt) |
MX (1) | MX2014008373A (pt) |
RU (1) | RU2623441C2 (pt) |
WO (1) | WO2013110578A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130197059A1 (en) * | 2012-01-27 | 2013-08-01 | Hoffmann-La Roche Inc. | Integrin antagonist conjugates for targeted delivery to cells expressing lfa-1 |
US9447035B2 (en) * | 2012-01-27 | 2016-09-20 | Hoffmann-La Roche Inc. | Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4 |
CA2854254A1 (en) * | 2012-01-27 | 2013-08-01 | F. Hoffmann-La Roche Ag | Integrin antagonist conjugates for targeted delivery to cells expressing vla-4 |
EP3030244B1 (en) * | 2013-08-07 | 2021-04-21 | Arrowhead Pharmaceuticals, Inc. | Polyconjugates for delivery of rnai triggers to tumor cells in vivo |
EP3939989A1 (en) | 2016-11-11 | 2022-01-19 | Zealand Pharma A/S | Cyclic peptides multimers targeting alpha 4beta 7 integrin |
CN110283223B (zh) * | 2018-03-19 | 2022-01-04 | 广州市锐博生物科技有限公司 | 一种阳离子脂质分子及其在核酸递送中的应用 |
IL309955A (en) * | 2018-04-27 | 2024-03-01 | Arrowhead Pharmaceuticals Inc | Integrin-targeting ligands and their uses |
JP2022500464A (ja) | 2018-09-11 | 2022-01-04 | サッツ, スタンレイSATZ, Stanley | Her2+癌および他の新生物の標的放射性核種治療および分子イメージング及び精密治療 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2185009T3 (es) * | 1996-04-10 | 2003-04-16 | Merck & Co Inc | Antagonistas de alfa y beta 3'. |
RU2001132141A (ru) * | 1999-04-28 | 2004-03-20 | БАСФ Акциенгезельшафт (DE) | Антагонисты интегриновых рецепторов |
ITRM20040241A1 (it) * | 2004-05-13 | 2004-08-13 | Ist Naz Stud Cura Dei Tumori | Camptotecine coniugate in posizione 20 con antagonisti delle integrine. |
US7300940B2 (en) * | 2004-08-04 | 2007-11-27 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Integrin α-v β-3 antagonists for use in imaging and therapy |
EA013323B1 (ru) * | 2004-12-09 | 2010-04-30 | Сентокор, Инк. | Иммуноконъюгаты против интегрина, способы и варианты применения |
US8686044B2 (en) | 2008-08-13 | 2014-04-01 | Mitsui Chemicals Agro, Inc. | Amide derivative, pest control agent containing the amide derivative, and use of the amide derivative |
US9139554B2 (en) | 2008-10-09 | 2015-09-22 | Tekmira Pharmaceuticals Corporation | Amino lipids and methods for the delivery of nucleic acids |
-
2013
- 2013-01-22 BR BR112014016736A patent/BR112014016736A8/pt active Search and Examination
- 2013-01-22 ES ES13701748.9T patent/ES2605939T3/es active Active
- 2013-01-22 KR KR1020147023904A patent/KR20150009952A/ko not_active Application Discontinuation
- 2013-01-22 CA CA2856619A patent/CA2856619A1/en not_active Abandoned
- 2013-01-22 JP JP2014553678A patent/JP6316209B2/ja not_active Expired - Fee Related
- 2013-01-22 EP EP13701748.9A patent/EP2806899B1/en active Active
- 2013-01-22 MX MX2014008373A patent/MX2014008373A/es unknown
- 2013-01-22 RU RU2014132565A patent/RU2623441C2/ru not_active IP Right Cessation
- 2013-01-22 CN CN201380006790.8A patent/CN104144706B/zh active Active
- 2013-01-22 WO PCT/EP2013/051082 patent/WO2013110578A1/en active Application Filing
- 2013-01-22 US US14/374,680 patent/US9586916B2/en active Active
-
2015
- 2015-03-23 HK HK15102940.0A patent/HK1202426A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
ES2605939T3 (es) | 2017-03-17 |
MX2014008373A (es) | 2014-09-26 |
CN104144706A (zh) | 2014-11-12 |
RU2623441C2 (ru) | 2017-06-26 |
EP2806899A1 (en) | 2014-12-03 |
HK1202426A1 (en) | 2015-10-02 |
RU2014132565A (ru) | 2016-03-20 |
WO2013110578A1 (en) | 2013-08-01 |
CA2856619A1 (en) | 2013-08-01 |
JP6316209B2 (ja) | 2018-04-25 |
US20150038523A1 (en) | 2015-02-05 |
EP2806899B1 (en) | 2016-10-19 |
US9586916B2 (en) | 2017-03-07 |
CN104144706B (zh) | 2017-03-29 |
KR20150009952A (ko) | 2015-01-27 |
BR112014016736A8 (pt) | 2017-07-04 |
JP2015506946A (ja) | 2015-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014008126A2 (pt) | composto, método para o tratamento, composição farmacêutica, utilização de um composto e invenção | |
BR112014032053A2 (pt) | composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção | |
BR112014010179A8 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
BR112014003681A8 (pt) | composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições | |
BR112014011671A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto | |
BR112014029530A2 (pt) | compostos, composição farmacêutica e uso de um composto | |
BR112015000420A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BR112014007203A2 (pt) | composto, composição farmacêutica, método de tratamento, utilização de um composto, conjunto e invenção | |
BR112014001346A2 (pt) | composto nanotransportador, método, composto farmacêutico e uso de um composto | |
BR112014029115A2 (pt) | composto, composição farmacêutica, e, uso de um composto ou composição | |
BR112015001830A2 (pt) | composto, uso de um composto, método para o tratamento ou profilaxia de câncer e invenção | |
BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
BR112015004547A2 (pt) | compostos, composição farmacêutica, uso de um composto e método para o tratamento ou melhoria do cãncer | |
BR112014001255A2 (pt) | composto, uso de um composto, combinação, e, composição farmacêutica | |
BR112014013760A2 (pt) | composto, composição farmacêutica e uso de um composto | |
BR112015004489A2 (pt) | composto, composição farmacêutica, e, métodos para tratar um distúrbio proliferativo e para sintetizar um composto | |
BR112012026570A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado | |
BR112014003802A2 (pt) | composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento | |
BR112014005669A2 (pt) | composto, composição farmacêutica e uso de um composto | |
BR112014029404A2 (pt) | compostos , composição farmacêutica, utilização de um composto, método para o tratamento ou profilaxia do cancêr e invenção | |
BR112014032510A2 (pt) | composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto. | |
BR112014003567A2 (pt) | composto, uso de um composto, e, composição farmacêutica | |
BR112014016736A8 (pt) | composto, composição farmacêutica, método para tratamento, uso de um composto e invenção | |
BR112014031896A2 (pt) | composto, composição farmacêutica, e, método para o tratamento de um distúrbio | |
BR112014006420A2 (pt) | compostos, composição farmacêutica, uso de um composto e mètodo para o tratamento ou profilaxia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/00 (2006.01), A61P 35/00 (2006.01), A61P 2 |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] | ||
B07B | Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |